209482-01-9

Basic information

• Product Name: 1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine
• Synonyms: 1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine
• CAS NO: 209482-01-9
• Molecular Formula: C₁₂H₁₇N₃O₃
• Molecular Weight: 251.28168
• EINECS: -0
• Mol File: 209482-01-9.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 409.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.204±0.06 g/cm3(Predicted)
• PKA: 7.27±0.42(Predicted)
• CAS DataBase Reference: 1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine(209482-01-9)
• EPA Substance Registry System: 1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine(209482-01-9)

Safety Data

• Hazardous Substances Data: 209482-01-9(Hazardous Substances Data)

Usage

Description

1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine is a chemical compound belonging to the class of piperazine derivatives. It is a yellow solid with a molecular formula of C12H18N4O3 and a molecular weight of 258.3 g/mol, featuring a piperazine ring with a 2-methoxy-4-nitrophenyl group and a methyl group attached to it. 1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine is commonly used in pharmacological research and drug development, making it a promising target for medicinal chemistry studies due to its unique chemical structure.

Uses

Used in Pharmaceutical Research:
1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine is used as a research compound for the development of new drugs targeting various diseases and conditions. Its unique chemical structure allows for the exploration of its potential therapeutic effects and mechanisms of action.
Used in Medicinal Chemistry Studies:
In the field of medicinal chemistry, 1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine is used as a starting material or a structural motif for the design and synthesis of novel compounds with potential therapeutic applications. Its chemical properties and structural features make it an attractive candidate for further modification and optimization to enhance its pharmacological properties.
Used in Drug Delivery Systems:
1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine may also be employed in the development of drug delivery systems, where its chemical properties can be utilized to improve the bioavailability, targeting, and overall efficacy of therapeutic agents. This application can be particularly useful in the context of targeted drug delivery, where the compound's structural features can be exploited to enhance the selectivity and specificity of drug action.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 1009-36-5 2-chloro-5-nitroanisole 
• 77337-82-7 1-bromo-2-methoxy-4-nitrobenzene 
• 7787-70-4 copper(I) bromide 
• 454-16-0 1-fluoro-2-methoxy-4-nitrobenzene 

Downstream Products

• 156428-85-2 3-methoxy-4-(4-methylpiperazin-1-yl)aniline 
• 1404437-49-5 N-(3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine 

Relevant articles and documents

COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS

Provided are compounds of Formula (I) which can be used as Syk inhibitors and potently as therapeutic agents against diseases mediated by Syk.

The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations

EGFR mutations are an ongoing challenge in the treatment of NSCLC, and demand continuous updating of EGFR TKI drug candidates. Pyrrolopyrimidines are one group of versatile scaffolds suitable for tailored drug development. However not many precedents of this type of pharmacophore have been investigated in the realm of third generation of covalent EGFR-TKIs. Herein, a series of pyrrolo[2,3-d]pyrimidine derivatives able to block mutant EGFR activity in a covalent manner were synthesized, through optimized Buchwald-Hartwig C–N cross coupling reactions. Their preliminary bioactivity and corresponding inhibitory mechanistic pathways were investigated at molecular and cellular levels. Several compounds exhibited increased biological activity and enhanced selectivity compared to the control compound. Notably, compound 12i selectively inhibits HCC827 cells harboring the EGFR activating mutation with up to 493-fold increased efficacy compared to in normal HBE cells. Augmented selectivity was also confirmed by kinase enzymatic assay, with the test compound selectively inhibiting the T790 M activating mutant EGFRs (IC50 values of 0.21 nM) with up to 104-fold potency compared to the wild-type EGFR (IC50 values of 22 nM). Theoretical simulations provide structural evidence of selective kinase inhibitory activity. Thus, this series of pyrrolo[2,3-d]pyrimidine derivatives could serve as a starting point for the development of new EGFR-TKIs.

Pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as preparation method and application of pyrrolo [2, 3-d] pyrimidine derivative

The invention provides a pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as a preparation method and application thereof, and belongs to the field of chemical medicines. The derivative is a compound shown as a formula I, or a salt t